Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Yasuhiko Harada"'
Autor:
Tomoaki Haga, Takahiro Okumura, Yasuhiko Harada, Hiroaki Hiraiwa, Ryota Morimoto, Shinji Kaneko, Nagaaki Kato, Masanori Shinoda, Toyoaki Murohara
Publikováno v:
The Egyptian Heart Journal, Vol 76, Iss 1, Pp 1-5 (2024)
Abstract Background Myeloproliferative disorders, including monoclonal gammopathy of undetermined significance (MGUS), are often associated with amyloid light-chain (AL)-type cardiac amyloidosis (CA) but occasionally with wild-type transthyretin (ATT
Externí odkaz:
https://doaj.org/article/79a2a7a76f4442619d1f22c5f66c1bb9
Autor:
Hikaru Hattori, Yuichi Ishikawa, Naomi Kawashima, Akimi Akashi, Yohei Yamaguchi, Yasuhiko Harada, Daiki Hirano, Yoshiya Adachi, Kotaro Miyao, Yoko Ushijima, Seitaro Terakura, Tetsuya Nishida, Tadashi Matsushita, Hitoshi Kiyoi
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0204850 (2018)
All-trans retinoic acid (ATRA) and arsenic trioxide (ATO) are essential for acute promyelocytic leukemia (APL) treatment. It has been reported that mutations in PML-RARA confer resistance to ATRA and ATO, and are associated with poor prognosis. Altho
Externí odkaz:
https://doaj.org/article/b018da3d5d7945b5863aa8ddd9d5bd03
Autor:
Keisuke Iwata, Yasuhiko Harada, Tomoki Yoshioka, Hisashi Kurata, Junji Hiraga, Yoshitoyo Kagami
Publikováno v:
Nihon Naika Gakkai Zasshi. 110:1633-1640
Publikováno v:
Internal medicine (Tokyo, Japan). 61(14)
Objective Follicular lymphoma (FL) is an indolent B-cell malignancy, usually treated by immunochemotherapy in advanced-stage and high-tumor-burden cases. Although some reports have shown no significant relationship between the pre-treatment body mass
Autor:
Fumiya, Ohara, Yasuhiko, Harada, Yoshimasa, Tanikawa, Michihiko, Narita, Yoshitoyo, Kagami, Junji, Hiraga
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 62(7)
We report the case of a 62-year-old woman with multiple liver tumors. She was diagnosed with synchronous occurrence of multiple myeloma (MM) and primary pulmonary adenocarcinoma 4 years ago. She was treated with bortezomib and dexamethasone for MM, a
Autor:
Yasuhiko, Harada, Makoto, Murata, Akane, Matsumoto, Daizo, Kato, Tetsuya, Yagi, Takashi, Yaguchi, Takenori, Yoshikawa, Takuya, Takeichi, Masashi, Akiyama, Yohei, Yamaguchi, Daisuke, Koyama, Seitaro, Terakura, Tetsuya, Nishida, Hitoshi, Kiyoi
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 60(12)
A 47-year-old man with acute myeloid leukemia and myelodysplastic-related changes relapsed after an allogenic bone marrow transplant and received a cord blood transplant as salvage therapy. The patient developed febrile neutropenia that was resistant
Autor:
Kazuyuki Shimada, Yuki Kojima, Seiichi Kato, Shunsuke Kuno, Akihiro Tomita, Tomohiro Aoki, Chisako Iriyama, Hitoshi Kiyoi, Akihiko Sakamoto, Fumihiko Hayakawa, Takanobu Morishita, Yasuhiko Harada, Keiki Sugimoto, Satoko Shimada
Publikováno v:
Oncotarget
// Tomohiro Aoki 1 , Kazuyuki Shimada 1, 2 , Akihiko Sakamoto 1, 5 , Keiki Sugimoto 1, 3 , Takanobu Morishita 1, 6 , Yuki Kojima 1 , Satoko Shimada 4 , Seiichi Kato 4 , Chisako Iriyama 1 , Shunsuke Kuno 1 , Yasuhiko Harada 1 , Akihiro Tomita 1, 7 , F
Autor:
Shingo Okuno, Kotaro Suzuki, Shozo Okamura, Matsuyoshi Maeda, Isamu Sugiura, Yasuhiko Harada, Fumihiro Urano, Masahiro Yamada, Satoshi Nishiwaki, Shingo Kurahashi
Publikováno v:
Blood. 129:126-128
A positive fecal occult blood test (FOBT) is occasionally observed in some chronic myeloid leukemia (CML) patients treated with a tyrosine kinase inhibitor (TKI), and hemorrhagic colitis in patients treated with dasatinib has been reported. To clarif
Autor:
Tomohiro Kajiguchi, Hitoshi Kiyoi, Naomi Kawashima, Nobuaki Fukushima, Yukiyasu Ozawa, Rika Kihara, Marie Nakashima, Jeong Hui Kim, Koichi Watamoto, Tatsunori Goto, Kunio Kitamura, Yasuhiko Harada, Akio Kohno, Yoko Ushijima, Yuichi Ishikawa, Takahiro Nishiyama
Publikováno v:
Blood. 134:1418-1418
【Background】Recently, FLT3 inhibitors are approved for FLT3 mutated AML patients and other FLT3 inhibitors are also in clinical development. Since the target selectivity and the inhibitory activity of FLT3 inhibitors are varied, it is required to
Autor:
Yoshiya Adachi, Seitaro Terakura, Daiki Hirano, Hikaru Hattori, Hitoshi Kiyoi, Akimi Akashi, Yoko Ushijima, Tadashi Matsushita, Yohei Yamaguchi, Naomi Kawashima, Kotaro Miyao, Tetsuya Nishida, Yasuhiko Harada, Yuichi Ishikawa
Publikováno v:
PLoS ONE
PLoS ONE, Vol 13, Iss 10, p e0204850 (2018)
PLoS ONE, Vol 13, Iss 10, p e0204850 (2018)
All-trans retinoic acid (ATRA) and arsenic trioxide (ATO) are essential for acute promyelocytic leukemia (APL) treatment. It has been reported that mutations in PML-RARA confer resistance to ATRA and ATO, and are associated with poor prognosis. Altho